Skip to main content
Guidance

MenB vaccine: patient group direction template

PGD template to support the national meningococcal group B vaccination programme and public health management of meningococcal disease.

Applies to England

Documents

Meningococcal group B vaccine patient group direction (PGD) template

Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the administration of MenB vaccine to individuals from 8 weeks of age eligible for the national routine meningococcal group B vaccination programme and to individuals for the prevention of secondary cases of meningococcal group B disease in accordance with the guidance for the public health management of meningococcal disease in the UK.

The PGD template has been updated to include use of Trumenba® (f rLP2086) vaccine for the prevention of secondary cases of meningococcal group B disease as per guidance for the public health management of meningococcal disease in the UK as an alternative to Bexsero® vaccine where the infecting strain is confirmed or predicted not to be covered by Bexsero® vaccine.

Note: Trumenba® (f rLP2086) vaccine is not used for the national routine childhood immunisation programme.

MenB vaccine PGD template version 9.0 is valid from 1 December 2026 to 1 December 2029.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy and procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and summary of product characteristics for the vaccine.

Sign up for emails or print this page